NF-κB in carcinoma therapy and prevention

被引：52

作者：

Brown, Matthew ^{[1
]}

Cohen, Jonah ^{[1
]}

Arun, Pattatheyil ^{[1
]}

Chen, Zhong ^{[1
]}

Van Waes, Carter ^{[1
,2
,3
]}

机构：

[1] Natl Inst Deafncss & Other Commun Disorders, Head & Neck Surg Branch, Bethesda, MD 20892 USA

[2] NCI, Ctr Canc Res, Radiat Oncol Branch, Bethesda, MD 20892 USA

[3] Natl Inst Deafness & Other Commun Disorders, NIH, Head & Neck Surg Branch, Bethesda, MD 20892 USA

来源：

EXPERT OPINION ON THERAPEUTIC TARGETS | 2008年 / 12卷 / 09期

关键词：

aspirin; BMS-345541; bortezomib; carcinoma; CHS-828; dexamethasone; inhibitor-kappaB; MLN-120B; NF-kappa B; NSAIDs; proteasome; sulindac;

D O I：

10.1517/14728222.12.9.1109

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Background: NF-kappa B includes a family of signal-activated transcription factors that normally regulate responses to injury and infection but which are aberrantly activated in many carcinomas. Objective: To review the activation and role of NF-kappa B in pathogenesis and as a target for treatment and prevention in carcinoma. Methods: Evidence from experimental, epidemiological, preclinical studies and clinical trials cited in the literature are reviewed. Results/conclusion: Cumulative evidence implicates NF-kappa B in cell survival, inflammation, angiogenesis, spread and therapeutic resistance during tumor development, progression and metastasis of carcinomas. Non-specific natural and synthetic agents that inhibit NF-kappa B have demonstrated activity and safety in prevention or therapy. NF-kappa B-activating kinases and the proteasome are under investigation for targeted prevention and therapy of carcinoma.

引用

页码：1109 / 1122

页数：14

共 122 条

[41]

Hessenauer A, 2003, INT J ONCOL, V22, P1263

[42]

HEWAMANA S, 2008, BLOOD

[43] NF-κB as a therapeutic target in multiple myeloma [J].

Hideshima, T ;

Chauhan, D ;

Richardson, P ;

Mitsiades, C ;

Mitsiades, N ;

Hayashi, T ;

Munshi, N ;

Dang, L ;

Castro, A ;

Palombella, V ;

Adams, J ;

Anderson, KC .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (19) :16639-16647

[44] MLN120B, a novel IκB kinase β inhibitor, blocks multiple myeloma cell growth in vitro and in vivo [J].

Hideshima, Teru ;

Neri, Paola ;

Tassone, Pierfranchesco ;

Yasui, Hiroshi ;

Ishitsuka, Kenji ;

Raje, Noopur ;

Chauhan, Dharminder ;

Podarl, Klaus ;

Mitsiades, Constantine ;

Dang, Lenny ;

Munshi, Nikhil ;

Richardson, Paul ;

Schenkein, David ;

Anderson, Kenneth C. .

CLINICAL CANCER RESEARCH, 2006, 12 (19) :5887-5894

[45] Nuclear factor κB-dependent gene expression profiling of Hodgkin's disease tumor cells, pathogenetic significance, and link to constitutive signal transducer and activator of transcription 5a activity [J].

Hinz, M ;

Lemke, P ;

Anagnostopoulos, I ;

Hacker, C ;

Krappmann, D ;

Mathas, S ;

Dörken, B ;

Zenke, M ;

Stein, H ;

Scheidereit, C .

JOURNAL OF EXPERIMENTAL MEDICINE, 2002, 196 (05) :605-617

[46] Hostile takeovers:: viral appropriation of the NF-κB pathway [J].

Hiscott, J ;

Kwon, H ;

Génin, P .

JOURNAL OF CLINICAL INVESTIGATION, 2001, 107 (02) :143-151

[47] Circuitry of nuclear factor κB signaling [J].

Hoffmann, A ;

Baltimore, D .

IMMUNOLOGICAL REVIEWS, 2006, 210 :171-186

[48]

Hovstadius P, 2002, CLIN CANCER RES, V8, P2843

[49] Sequential modification of NEMO/IKKγ by SUMO-1 and ubiquitin mediates NF-κB activation by genotoxic stress [J].

Huang, TT ;

Wuerzbrger-Davis, SM ;

Wu, ZH ;

Miyamoto, S .

CELL, 2003, 115 (05) :565-576

[50] POTENT INHIBITORS OF PROTEASOME [J].

IQBAL, M ;

CHATTERJEE, S ;

KAUER, JC ;

DAS, M ;

MESSINA, P ;

FREED, B ;

BIAZZO, W ;

SIMAN, R .

JOURNAL OF MEDICINAL CHEMISTRY, 1995, 38 (13) :2276-2277

← 1 2 3 4 5 6 7 8 9 10 →